Related Experiment Video
Updated: May 20, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Sunitinib and pancreatic neuroendocrine tumours. More assessment needed
Abstract:
There is no standard first-line cytotoxic chemotherapy for patients with metastatic or inoperable well-differentiated pancreatic neuroendocrine tumours. All available regimens have significant toxicity. Sunitinib, a tyrosine kinase inhibitor, has been authorised for oral administration in this situation. Sunitinib has not been compared with cytotoxic regimens. Clinical evaluation is based on a double-blind randomised placebo-controlled trial that was halted prematurely after 171 patients had been treated for a median of about 10 months. During the trial, there were 9 deaths in the sunitinib group versus 21 deaths in the placebo group. The median progression-free survival time was statistically significantly longer with sunitinib than with placebo (11.4 versus 5.5 months), but the results are undermined by methodological issues. Adverse events classified as serious by the investigators (neutropenia, hypertension, palmoplantar erythrodysaesthesia, etc.) occurred in about 13% of patients in the sunitinib group versus 7% of patients in the placebo group. Two patients treated with sunitinib died of heart failure. More assessment of sunitinib is needed. The only available trial, a placebo-controlled study, failed to show whether the benefits outweigh the risks.
Insights
Sunitinib, a targeted therapy, showed longer progression-free survival for advanced pancreatic neuroendocrine tumors compared to placebo. However, serious adverse events and methodological issues warrant further investigation into its risk-benefit profile.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic or inoperable well-differentiated pancreatic neuroendocrine tumors lack a standard first-line cytotoxic chemotherapy.
- Existing chemotherapy regimens are associated with significant toxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of sunitinib, an oral tyrosine kinase inhibitor, as a first-line treatment for metastatic or inoperable well-differentiated pancreatic neuroendocrine tumors.
- To compare sunitinib with placebo in this patient population.
Main Methods:
- A double-blind, randomized, placebo-controlled trial was conducted.
- The trial was prematurely halted after treating 171 patients for a median of approximately 10 months.
Main Results:
- Median progression-free survival was significantly longer with sunitinib (11.4 months) compared to placebo (5.5 months).
- Serious adverse events occurred in 13% of patients on sunitinib versus 7% on placebo.
- Deaths occurred in 9 patients in the sunitinib group and 21 in the placebo group, with two sunitinib-related deaths attributed to heart failure.
Conclusions:
- While sunitinib demonstrated improved progression-free survival, methodological limitations of the study complicate the interpretation of benefits versus risks.
- Further assessment of sunitinib is required to determine its overall benefit-risk balance in this indication.